Heron Therapeutics Inc. Overview
Heron Therapeutics, Inc., a biotechnology company based in San Diego, United States, operates within the Health Care sector. The company is renowned for its proprietary biochronomer drug delivery technology, which aims to enhance the therapeutic profile of injectable pharmaceuticals. Heron Therapeutics is also focused on identifying existing therapies that can be reformulated to improve their efficacy and delivery.
Financial Snapshot
As of August 6, 2025, Heron Therapeutics Inc. closed at a price of $1.84 on the Nasdaq stock exchange. The company’s market capitalization stands at approximately $263.94 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $2.68 on March 4, 2025, and a 52-week low of $1.04 on November 11, 2024. The price-to-earnings ratio is currently at -34.22, reflecting the company’s financial performance and market expectations.
Company Background
Heron Therapeutics was established with its Initial Public Offering (IPO) on August 26, 1987. The company has since been a key player in the biotechnology industry, leveraging its innovative drug delivery technology to advance therapeutic solutions. For more detailed information about their activities and developments, interested parties can visit their website at www.herontx.com .
Industry Position
Operating in the biotechnology sector, Heron Therapeutics is part of a dynamic industry focused on developing cutting-edge medical solutions. The company’s emphasis on reformulating existing therapies positions it uniquely within the market, potentially offering improved treatment options for various medical conditions.
Conclusion
Heron Therapeutics Inc. continues to be a significant entity in the biotechnology landscape, driven by its innovative approach to drug delivery and reformulation. Despite recent financial challenges, as indicated by its negative price-to-earnings ratio, the company remains committed to advancing healthcare solutions through its proprietary technologies.